glp-1 gip Frontiers GLP1-GIP receptor co-agonists: a promising

Harsha Varma S, Tirupati S, Pradeep TVS, et al

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): A randomised, double-blind, placebo-controlled phase 2b trial

the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally

In Phase 2 trials, treatment with survodutide led to greater reductions in both HbA1c levels and body weight compared to placebo after 16 weeks

SGLT2-i reduces both systolic blood pressure (SBP) and diastolic blood pressure (DBP) across multiple trials and meta-analyses with reductions up to 8.6/4.3 mmHg, depending on the agent, dose and population studied

Costs and results of different weight loss treatments after 5 years: Such a cost comparison is one of the most compelling reasons for bariatric surgery: a one-off operation costs far less than 1-2 years of pharmaceuticals and produces 10-20 times as much weight loss